Griffin et al. performed an in vivo CRISPR screen to discover epigenetic modulators of immune checkpoint blockade (ICB) response and identified the repressive histone methyltransferase SETDB1 as a potent mediator of ICB resistance in mouse melanoma and lung carcinoma models [129]. Here, SETDB1 is linked to melanoma.